Prevalence of hypertension among patients aged 50 and older living with human immunodeficiency virus.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
Apr 2019
Historique:
entrez: 16 4 2019
pubmed: 16 4 2019
medline: 23 4 2019
Statut: ppublish

Résumé

Hypertension is one of the common medical conditions observed among patients aged 50 years and elder living with HIV (EPLWH) and to date no systematic review has estimated its global prevalence. To conduct a systematic review to estimate the global prevalence of hypertension among EPLWH. PubMed/MEDLINE, Embase, the Cochrane Library, and Global Health databases for relevant publications up till May 25, 2018. Observational studies (cohort or cross-sectional studies) that estimated the prevalence of hypertension among EPLWH. Required data were extracted independently by three reviewers and the main outcome was hypertension prevalence among EPLWH. The 24 (n = 29,987) eligible studies included were conducted in North America, Europe, Africa, and Asia. A low level bias threat to the estimated hypertension prevalence rates was observed. The global prevalence of hypertension among EPLWH was estimated at 42.0% (95% CI 29.6%-55.4%), I = 100%. The subgroup analysis showed that North America has the highest prevalence of hypertension 50.2% (95% CI 29.2% -71.2%) followed by Europe 37.8% (95% CI 30.7%-45.7%) sub-Saharan Africa 31.9% (95% CI 18.5% -49.2%) and Asia 31.0% (95% CI 26.1%-36.3%). We found the mean age of the participants explaining a considerable part of variation in hypertension prevalence. This study demonstrated that two out of five EPLWH are hypertensive. North America appears to have the highest prevalence of hypertension followed by Europe, sub-Saharan Africa (SSA) and Asia respectively. Findings from this study can be utilized to integrate hypertension management to HIV management package. (Registration number: CRD42018103069).

Sections du résumé

BACKGROUND BACKGROUND
Hypertension is one of the common medical conditions observed among patients aged 50 years and elder living with HIV (EPLWH) and to date no systematic review has estimated its global prevalence.
PURPOSE OBJECTIVE
To conduct a systematic review to estimate the global prevalence of hypertension among EPLWH.
DATA SOURCES METHODS
PubMed/MEDLINE, Embase, the Cochrane Library, and Global Health databases for relevant publications up till May 25, 2018.
STUDY SELECTION METHODS
Observational studies (cohort or cross-sectional studies) that estimated the prevalence of hypertension among EPLWH.
DATA EXTRACTION METHODS
Required data were extracted independently by three reviewers and the main outcome was hypertension prevalence among EPLWH.
DATA SYNTHESIS RESULTS
The 24 (n = 29,987) eligible studies included were conducted in North America, Europe, Africa, and Asia. A low level bias threat to the estimated hypertension prevalence rates was observed. The global prevalence of hypertension among EPLWH was estimated at 42.0% (95% CI 29.6%-55.4%), I = 100%. The subgroup analysis showed that North America has the highest prevalence of hypertension 50.2% (95% CI 29.2% -71.2%) followed by Europe 37.8% (95% CI 30.7%-45.7%) sub-Saharan Africa 31.9% (95% CI 18.5% -49.2%) and Asia 31.0% (95% CI 26.1%-36.3%). We found the mean age of the participants explaining a considerable part of variation in hypertension prevalence.
CONCLUSION CONCLUSIONS
This study demonstrated that two out of five EPLWH are hypertensive. North America appears to have the highest prevalence of hypertension followed by Europe, sub-Saharan Africa (SSA) and Asia respectively. Findings from this study can be utilized to integrate hypertension management to HIV management package. (Registration number: CRD42018103069).

Identifiants

pubmed: 30985651
doi: 10.1097/MD.0000000000015024
pii: 00005792-201904120-00012
pmc: PMC6485838
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15024

Références

Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Int J Health Policy Manag. 2014 Aug 13;3(3):123-8
pubmed: 25197676
Lancet. 2007 Jul 7;370(9581):59-67
pubmed: 17617273
Clin Infect Dis. 2011 Dec;53(11):1130-9
pubmed: 21998280
AIDS. 2006 Nov 14;20(17):2165-74
pubmed: 17086056
Am J Ther. 2006 May-Jun;13(3):248-60
pubmed: 16772767
Stat Med. 1999 Feb 15;18(3):321-59
pubmed: 10070677
AIDS Rev. 2015 Apr-Jun;17(2):83-95
pubmed: 26035166
Clin Infect Dis. 2003 Jul 15;37(2):292-8
pubmed: 12856222
N Engl J Med. 2005 Jan 6;352(1):48-62
pubmed: 15635112
J Pathol. 2008 Jan;214(2):231-41
pubmed: 18161758
Ann Intern Med. 2006 Sep 19;145(6):397-406
pubmed: 16983127
Neurology. 2004 Sep 14;63(5):822-7
pubmed: 15365130
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Hypertension. 2001 Mar;37(3):869-74
pubmed: 11244010
Ann Intern Med. 2009 Aug 18;151(4):264-9, W64
pubmed: 19622511
J Gerontol A Biol Sci Med Sci. 2007 Nov;62(11):1279-86
pubmed: 18000149
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
JAMA Intern Med. 2013 Apr 22;173(8):614-22
pubmed: 23459863
N Engl J Med. 1998 Mar 26;338(13):853-60
pubmed: 9516219
Chest. 2006 Nov;130(5):1326-33
pubmed: 17099007
Atherosclerosis. 2005 Jan;178(1):165-72
pubmed: 15585214
Atherosclerosis. 2006 Apr;185(2):361-7
pubmed: 16137695
Clin Gastroenterol Hepatol. 2010 Dec;8(12):1002-12
pubmed: 20851211
Ann Intern Med. 2009 Aug 18;151(4):W65-94
pubmed: 19622512
Postgrad Med J. 2007 Feb;83(976):109-14
pubmed: 17308214
J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):91-8
pubmed: 26322669
J Am Soc Hypertens. 2017 Aug;11(8):530-540
pubmed: 28689734
Acta Trop. 2009 Nov;112 Suppl 1:S8-S15
pubmed: 19695211
J Hypertens Suppl. 1999 Dec;17(5):S29-36
pubmed: 10706323
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Nephrol Dial Transplant. 2012 Jun;27(6):2291-7
pubmed: 22121232
Syst Rev. 2014 Jun 23;3:60
pubmed: 24956937
AIDS. 2010 Nov 27;24(18):2827-33
pubmed: 21045635
Atherosclerosis. 2011 Feb;214(2):468-73
pubmed: 21130995
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
AIDS. 2010 Jun 19;24(10):1527-35
pubmed: 20467289
N Engl J Med. 2010 Jul 15;363(3):257-65
pubmed: 20647201
Atherosclerosis. 2009 Dec;207(2):524-9
pubmed: 19515371
J Clin Epidemiol. 2016 Feb;70:38-44
pubmed: 26261004
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Patrick Dakum (P)

Institute of Human Virology.

Gbenga Ayodele Kayode (GA)

International Research Centre of Excellence, Institute of Human Virology, Nigeria, Maina Court, Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands.

Alash'le Abimiku (A)

International Research Centre of Excellence, Institute of Human Virology, Nigeria, Maina Court, Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
Institute of Human Virology University of Maryland School of Medicine, Baltimore.

Yohanna Kambai Avong (YK)

Institute of Human Virology.

James Okuma (J)

Institute of Human Virology.

Ezenwa Onyemata (E)

Institute of Human Virology.
International Research Centre of Excellence, Institute of Human Virology, Nigeria, Maina Court, Herbert Macaulay Way, Central Business District, Abuja, Nigeria.

Taofeekat Ali (T)

Institute of Human Virology.

Victor Adekanmbi (V)

International Research Centre of Excellence, Institute of Human Virology, Nigeria, Maina Court, Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
Division of Population Medicine, School of Medicine, Cardiff University, Cardiff.

Olalekan Uthman (O)

International Research Centre of Excellence, Institute of Human Virology, Nigeria, Maina Court, Herbert Macaulay Way, Central Business District, Abuja, Nigeria.
Warwick-Centre for Applied Health Research and Delivery, Division of Health Sciences, Warwick Medical School, The University of Warwick, Coventry.
International Health Group, Liverpool School of Tropical Medicine, Liverpool, Merseyside, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH